HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 33, 25065-25068, August 18, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/33/25065    most recent C000284200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kuang, A. A. Articles by Winoto, A. Search for Related Content PubMed PubMed Citation Articles by Kuang, A. A. Articles by Winoto, A. Social Bookmarking                      What's this?

ACCELERATED PUBLICATION
FADD Is Required for DR4- and DR5-mediated Apoptosis

LACK OF TRAIL-INDUCED APOPTOSIS IN FADD-DEFICIENT MOUSE EMBRYONIC FIBROBLASTS^*

Anna A. Kuang, Gretchen E. Diehl, Jianke Zhang^§, and Astar Winoto^¶

From the Department of Molecular and Cell Biology, Cancer Research Laboratory and Division of Immunology, University of California, Berkeley, California 94720-3200

Received for publication, April 25, 2000, and in revised form, June 19, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a member of the tumor necrosis factor family that can kill a wide variety of tumor cells but not normal cells. TRAIL-induced apoptosis in humans is mediated by its receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2). What constitutes the signaling molecules downstream of these receptors, however, remains highly controversial. Using the FADD dominant negative molecule, several groups have reached different conclusions with respect to the role of FADD in TRAIL-induced apoptosis. More recently, using FADD-deficient (/) mouse embryonic fibroblasts, Yeh et al. (Yeh, W.-C., Pompa, J. L., McCurrach, M. E., Shu, H.-B., Elia, A. J., Shahinian, A., Ng, M., Wakeham, A., Khoo, W., Mitchell, K., El-Deiry, W. S., Lowe, S. W., Goeddel, D. V., and Mak, T. W. (1998) Science 279, 1954-1958) concluded that DR4 utilizes a FADD-independent apoptotic pathway. The latter experiment, however, involved transient overexpression, which often leads to nonspecific aggregation of death domain-containing receptors. To address this issue in a more physiological setting, we stably transfected mouse DR4/5, human DR4, or human DR5 into FADD^/ mouse embryonic fibroblast cells. We showed that FADD^/ MEF cells stably transfected with TRAIL receptors are resistant to TRAIL-mediated cell death. In contrast, TRAIL receptors stably transfected into heterozygous FADD^+/ cells or FADD^/ cells reconstituted with a FADD retroviral construct are sensitive to the TRAIL cytotoxic effect. We conclude that FADD is required for DR4- and DR5-mediated apoptosis.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

TRAIL,¹ also called Apo2L, is a member of the TNF family that can kill a variety of tumors but not normal cells, but its physiological function remains unknown. Several receptors that bind to TRAIL in humans have been identified. These include the death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2), decoy receptors DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4), and osteoprotegerin (2-4, 8-15). In mouse, we (data not shown) and others (16) have identified a gene encoding a protein with equivalent homology to human DR4 and DR5.

Fas, TNF-R1, and DR3, the first three identified death domain-containing receptors, initiate apoptosis through recruitment of a common adapter protein FADD. FADD in turn recruits caspase 8 to form the death-inducing signaling complex, which leads to activation of a caspase cascade and eventual cell-death. FADD^/ MEFs are resistant to FasL or TNF-induced apoptosis and apoptosis mediated by DR3 overexpression. The role of FADD in TRAIL receptors, however, is highly controversial. The association between FADD and DR4 or DR5 has been inconsistent in the literature. Several initial papers showed that the dominant negative FADD protein failed to inhibit apoptosis initiated by DR4 and DR5 overexpression (2-4, 15). However, other groups reported inhibition of DR4/5 apoptosis in FADD dominant negative transfected cells (1, 5, 17). Use of the FADD dominant negative mutant raised concerns that it could potentially inhibit other proteins. Yeh et al. (7) overexpressed DR4 by transient transfection in FADD^/ MEFs, which led to apoptosis. The authors concluded that FADD was not required for DR4- and possibly DR5-mediated apoptosis. However, as transfection of a death receptor often leads to nonspecific aggregation of their death domains, it still is not clear if FADD is involved in the physiological setting of TRAIL-induced cell death. By utilizing FADD^+/ and FADD ^/ MEFs that are stably transfected with mouse DR4/5, human DR4, or human DR5, we show that FADD is essential for TRAIL-mediated apoptosis.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Generation of Mouse Embryonic Fibroblasts-- FADD^+/ and FADD^/day 9.5 embryos were genotyped by polymerase chain reaction (18) and mechanically disrupted by passage through a 26-gauge syringe in 1 ml of trypsin solution. The cells were cultured and passaged in complete Dulbecco's modified Eagle's medium with 10% FCS. The presence or absence of the FADD protein in these cells was confirmed by Western blot using anti-FADD antibodies.

Cloning-- We used the human DR4 sequence to perform a BLAST search of the mouse EST data base to obtain a clone AI45268. Primers from the EST sequence were used to perform 5' and 3' rapid amplification of cDNA ends-PCR using a mouse spleen cDNA library to obtain a longer clone. This longer clone was used to screen a thymus cDNA phage library to obtain a full-length cDNA clone, which was cloned into pCI-HA. This HA-mDR4/5 was then cloned into the PmeI site of MSCV-puro-PLAP. BOSC cells were transfected by calcium phosphate with empty vector or MSCV-mDR4/5-puro-PLAP to generate viral supernatants. FADD^+/ and FADD^/ MEFs were infected with respective viral supernatants. The cells were maintained in puromycin selection (10 mg/ml) and analyzed for PLAP by flow cytometry. pCMV1-flag-DR5 and pCDNA3-flag-DR4 were co-transfected with pTK-Hygro by LipofectAMINE^TM Plus. Cells were placed into hygromycin selection at 50 mg/ml. The mouse cDNA of FADD was cloned into the XhoI site of MSCV-zeo. Viral supernatants were obtained and used to infect FADD^/ MEF cells stably transfected with hDR4 or hDR5. Batch cultures were selected in the presence of 100 mg/ml zeocin.

Antibody and Western Blot-- The extracellular domain of mDR4/5 was obtained by PCR with gene-specific primer pairs for cloning into pGEX-2T to create a glutathione S-transferase fusion protein. The fusion protein was purified with glutathione-agarose beads and used as antigen to raise polyclonal antibodies in rabbits. For Western blot, cell extracts were generated using 1% Nonidet P-40 lysis buffer (18). Blots were secondarily probed with horseradish peroxidase anti-rabbit antibodies and were developed with enhanced chemiluminescence.

Cell Count and Flow Cytometry-- Cells were trypsinized and washed with flow buffer (1× phosphate-buffered saline with 2% FCS). The cells were then blocked in 10% goat serum for 15 min on ice and stained using mouse anti-human placental alkaline phosphatase (DAKO, clone 8B6) followed by goat anti-mouse phycoerythrin-conjugated antibody.

Cytotoxic Assays-- Cells were treated with increasing amounts of human recombinant TRAIL (Biomol) in the presence of 500 ng/ml cycloheximide for 24 h at 37 °C. Cells were analyzed for viability by either the crystal violet or the MTT assay. MTT was added to each sample to a final concentration of 1 mg/ml, and the cells were incubated for 3-4 h at 37 °C. The medium was removed, and isopropyl alcohol was added. Following color elution, absorbance at 595 nm was measured using an enzyme-linked immunosorbent assay reader.

Annexin V Assay-- Cells were stained for 15 min in 100 ml of annexin V buffer with 1-2 ml of annexin V-fluorescein isothiocyanate. An additional 400 ml of annexin V buffer was added to each sample, and the cells were analyzed on a Coulter EPICS XL flow cytometer.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

We established that FADD^+/ and FADD^/ MEFs were not sensitive to TRAIL. Addition of soluble human TRAIL to the mouse fibroblast line, L929, led to apoptosis but did not cause substantial death of either FADD^+/ or FADD^/ MEFs even in the presence of cycloheximide.² This could be due to either a lack or low level expression of TRAIL receptors. We therefore stably transfected both FADD^+/ and FADD^/ MEFs with the mouse TRAIL receptor expression plasmid. We identified a full-length mouse TRAIL receptor cDNA by screening a thymus cDNA library with a mouse EST probe homologous to human DR4 and DR5. Sequencing of this clone showed that it is identical to the reported mouse DR5 TRAIL receptor (16). However, because its predicted polypeptide is 39% identical and 56% homologous to both human DR4 and DR5 alike, it is not clear if this gene is the mouse ortholog of human DR4 or DR5. We will call this gene henceforth as mDR4/5. In transient transfection of 293T cells, expression of this gene leads to extensive apoptosis and PARP cleavage (data not shown). We then stably transfected mDR4/5 into MEF cells and established several individual clones. Two empty vector-transfected controls and three mDR4/5-transfected clones were chosen for further analysis. To detect the TRAIL receptor protein expression, polyclonal antibodies were generated using a GST fusion protein. The mDR4/5-specific antiserum detects a protein with the predicted molecular mass of 46 kDa (Fig. 1). This species is present only in extracts of mDR4/5 transiently transfected cells but not in nontransfected cells or MEF cells. A similar band was detected in three mDR4/5 stably transfected FADD heterozygous MEF cells (mDR2-2, mDR2-17, mDR2-30) and in three FADD^/ stably transfected cells (mDR2-4, mDR2-10, mDR2-11, Fig. 1).

View larger version (31K): [in this window] [in a new window]   Fig. 1.   Mouse DR4/5 stably transfected mouse embryonic fibroblasts. FADD+/ and FADD/ MEFs were stably infected with empty or mDR4/5-expressing virus. Expression of the mDR4/5 protein in specific clones (mDR2-2, mDR2-17, mDR2-30, mDR2-4, mDR2-10 and mDR2-11) was confirmed by Western blot analysis using polyclonal anti-mDR4/5 antibodies, which reveal an ~46-kDa protein (HA-tagged mDR4/5, arrow). Cell extract from 293T cells transiently transfected with mDR4/5 served as a positive control.

To assess the sensitivity of these transfected cells to TRAIL-mediated cell death, we subjected them to increasing amounts of human TRAIL protein in the presence of the protein inhibitor cycloheximide. Human TRAIL has been shown to induce apoptosis in both human and mouse cells alike (19, 20). As controls, the same cells are also treated with cycloheximide alone. As shown in Fig. 2A, apoptosis can clearly be seen in mDR4/5 stably transfected FADD^+/ cells, whereas control vector alone-transfected cells are resistant to TRAIL-induced cell death. In FADD^/ MEF cells, however, transfection of mDR4/5 did not confer TRAIL sensitivity. All three stably transfected cells are equally resistant to the same extent to TRAIL-mediated apoptosis as the vector alone-transfected cells (Fig. 2A, right panel). Similar results were also obtained by measuring annexin V, which detects translocation of phosphatidylserine from the inner to the outer leaflet of the cellular membrane in early apoptotic cells (Fig. 2B).

View larger version (22K): [in this window] [in a new window]   Fig. 2.   FADD is required for mDR4/5-mediated apoptosis. A, individual clones of FADD+/ and FADD/ MEFs stably transfected with vector or mDR4/5 (mDR) were treated with increasing amounts of TRAIL and 500 ng/ml cycloheximide. Cell survival was assayed by staining with crystal violet dye at 24 h and plotted as percent of control cultures (cycloheximide alone). B, representative clones of FADD+/ and FADD/ MEFs stably transfected with empty virus or mDR4/5 were incubated with 500 ng/ml cycloheximide either in the presence or absence of 3 mg/ml TRAIL. Cells were assayed for apoptosis after 48 h by staining with annexin V.

To see if the requirement for FADD in TRAIL-mediated apoptosis also applies to the human receptors, we expressed human DR4 or human DR5 into FADD-deficient MEF cells by stable transfection. Expression of the human receptors was confirmed by reverse transcription-PCR with gene-specific primers (Fig. 3 and data not shown). For further analysis, we selected four DR4- and three DR5-transfected clones. As shown in Fig. 4, none of these cells is sensitive to the addition of human TRAIL protein (Fig. 4A, dashed lines, and Fig. 4B, left panel). To restore FADD function, a retroviral construct expressing mouse FADD was transduced into all the DR4- and DR5-transfected FADD^/ clones. Western blot analysis with FADD-specific antisera showed that FADD is expressed at high levels in these cells (Fig. 3). Addition of TRAIL to these cells led to apoptosis in a dose-dependent manner. Apoptosis can be seen in all DR4- or DR5-expressing cells (Fig. 4A), and the extent of cell death is similar to a known TRAIL-sensitive mouse cell line, L929 (19, 20). This is further confirmed by annexin V assay (Fig. 4B).

View larger version (41K): [in this window] [in a new window]   Fig. 3.   Stable expression of human DR4 and DR5 in FADD/ and FADD-reconstituted MEF cells. A, FADD/ MEFs were stably transfected with hDR4 or hDR5, and the presence of these transcripts was confirmed by reverse transcription-PCR. As a negative control, each reaction was also performed without reverse transcriptase (RT). B, expression of FADD (arrow) in FADD+/ not FADD/ MEFs was confirmed in Western blot analysis using rabbit anti-mouse FADD antibodies (lanes 1 and 2). The same analysis was performed using cell extracts from FADD/ cells stably transfected with hDR4 or hDR5 and infected with either empty or FADD-containing virus (lanes 3-10).

View larger version (25K): [in this window] [in a new window]   Fig. 4.   FADD is required for human DR4- and DR5-mediated apoptosis. A, individual clones of FADD/ cells stably transfected with hDR4 or hDR5 were infected with empty or FADD-containing virus. Each clone with or without FADD reconstitution was incubated with increasing amounts of TRAIL and 500 ng/ml cycloheximide. Cell survival (using MTT colorimetry assay) was assessed after 24 h and plotted as percent of control cultures (cycloheximide alone). The mouse fibroblast cell line, L929, which is TRAIL-sensitive, served as a positive control. B, representative stably transfected hDR4 or hDR5 FADD/ MEF clones were infected with empty or FADD-containing virus. Cells were incubated with 500 ng/ml cycloheximide either in the presence or absence of 1 mg/ml TRAIL. Cells were assayed for apoptosis after 36 h by staining with annexin V.

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The TNF receptor superfamily consists of many members with diverse functions. A subset of this family includes Fas, TNF-RI, DR3, DR4, and DR5, which all contain a death domain in their respective cytoplasmic tails. The signal transduction pathway of Fas-mediated apoptosis has been studied extensively (21-25). Fas forms a trimeric complex and upon stimulation by FasL, recruits FADD (26, 27), an adapter molecule consisting of a death domain and a death effector domain (28). FADD in turn interacts with a death effector domain-containing caspase (caspase 8), which activates a caspase cascade, leading to apoptosis (29, 30).

Although the role of FADD in Fas, TNF-RI, and DR3 has been clearly established (7, 31, 32), its role in TRAIL-mediated apoptosis has remained controversial. Whether FADD can interact with DR4 or DR5 is not clear, as different groups have reported conflicting data regarding the ability of FADD to associate with DR4 and DR5. Interaction by co-immunoprecipitation, however, can be difficult to detect because of the low abundance of the molecules or unfavorable lysis conditions. A case in point is the inability to detect the presence of FADD in the endogenous TNF-RI complex (33, 34). Despite this, FADD^/ MEFs are resistant to TNF-induced apoptosis (7), suggesting that TNF receptor utilizes FADD indirectly in initiating apoptosis. Thus, genetic studies are more definitive in establishing the importance of a protein in a signal transduction pathway. Dominant negative FADD has been reported to inhibit TRAIL-induced apoptosis (1, 5, 6, 17). However, overexpression of DR4 in FADD^/ MEFs can still lead to cell death (7). To address this issue, we used FADD^/ MEFs in a stable transfection assay to establish the role of FADD in TRAIL-induced cell death. FADD^+/ MEFs transfected with mouse DR4/5 are sensitive to TRAIL-mediated apoptosis in a dose-dependent manner. In contrast, FADD^/ MEFs expressing the mouse TRAIL receptor remain resistant to FADD. To correlate with the human system, we also transfected human DR4 or DR5 into FADD^/ cells. Despite expression of the TRAIL receptors, these cells remain resistant to TRAIL-mediated cell death. However, when these cells were reconstituted with the FADD molecule, they regained their TRAIL sensitivity. Thus, FADD is essential for the ability of TRAIL to initiate apoptosis. The discrepancy with the previous studies (7) is most likely due to the non-physiologically high level expression of the transiently transfected molecule, leading to either nonspecific toxicity or induction of an alternate pathway of apoptosis. Indeed, all receptors containing a death domain can induce apoptosis when transiently transfected into mammalian cells. However, in stably transfected cells or in physiological settings, expression of these receptors alone does not lead to cell death. Expression of the respective ligands in the same cells or contacting cells is necessary to initiate apoptosis.

While this work was in preparation, Bodmer et al. (35) reported that FADD and caspase 8 are recruited to the DR5 death-inducing signaling complex in Jurkat T cells that express DR5 but not DR4. Using these DR5-expressing Jurkat T cells deficient for FADD or caspase 8, they showed that these cells are resistant to TRAIL-mediated apoptosis. Their results confirm our findings with regard to DR5-mediated apoptosis. We extend these findings along with our FADD reconstitution studies to show that FADD is also required for DR4-mediated apoptosis.

In summary, we demonstrate that DR4- and DR5-mediated apoptosis depends critically upon FADD, and similar signaling pathways are used in both mouse and human cells. The essential role of FADD in apoptosis initiated by all the known death domain-containing TNF receptor family members may underscore the dramatic phenotype of FADD-deficient mice. These mice die by day 9.5 of gestation due to abnormal cardiac development (7, 18). In addition, T-cell receptor-mediated cell proliferation is defective in FADD-deficient T lymphocytes (18). This is in contrast to Fas- and TNF-RI-deficient mice, which are viable and exhibit no abnormalities until much later. Apoptosis and cell proliferation mediated by one or more of these TNF receptor members may therefore be crucial for mouse embryonic development and establishment of the immune system. Further gene targeting studies are necessary to establish the physiological role of the TRAIL receptors and other death domain-containing TNF receptor family members.

	ACKNOWLEDGEMENTS

We thank G. Pan and V. Dixit for hDR4 and hDR5 and J. Egen and B. Sha for retroviral constructs.

	FOOTNOTES

^* This work was supported by National Institutes of Health Grant CA75162 (to A. W.) and a grant from the National Science Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by a Howard Hughes Medical Institute Physician Postdoctoral Fellowship.

^§ Recipient of a Special Fellowship of the Leukemia Society of America.

^¶ To whom correspondence should be addressed. Tel.: 510-642-0217; Fax: 510-642-0468; E-mail: winoto@uclink4.berkeley.edu.

Published, JBC Papers in Press, June 21, 2000, DOI 10.1074/jbc.C000284200

² A. A. Kuang, G. Diehl, J. Zhang, and A. Winoto, unpublished data.

	ABBREVIATIONS

The abbreviations used are: TRAIL, TNF-related apoptosis inducing ligand; TNF, tumor necrosis factor; FADD, Fas-associated death domain protein; FCS, fetal calf serum; MEF, mouse embryonic fibroblasts; EST, expressed sequence tag; PLAP, placental alkaline phosphatase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PCR, polymerase chain reaction; MSCV, murine stem cell virus.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				V. Tur, A. M. van der Sloot, C. R. Reis, E. Szegezdi, R. H. Cool, A. Samali, L. Serrano, and W. J. Quax DR4-selective Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Variants Obtained by Structure-based Design J. Biol. Chem., July 18, 2008; 283(29): 20560 - 20568. [Abstract] [Full Text] [PDF]

				L. Tourneur, S. Mistou, A. Schmitt, and G. Chiocchia Adenosine Receptors Control a New Pathway of Fas-associated Death Domain Protein Expression Regulation by Secretion J. Biol. Chem., June 27, 2008; 283(26): 17929 - 17938. [Abstract] [Full Text] [PDF]

				R. M. Locklin, E. Federici, B. Espina, P. A. Hulley, R. G. G. Russell, and C. M. Edwards Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis Mol. Cancer Ther., December 1, 2007; 6(12): 3219 - 3228. [Abstract] [Full Text] [PDF]

				H. Matta, L. Mazzacurati, S. Schamus, T. Yang, Q. Sun, and P. M. Chaudhary Kaposi's Sarcoma-associated Herpesvirus (KSHV) Oncoprotein K13 Bypasses TRAFs and Directly Interacts with the I{kappa}B Kinase Complex to Selectively Activate NF-{kappa}B without JNK Activation J. Biol. Chem., August 24, 2007; 282(34): 24858 - 24865. [Abstract] [Full Text] [PDF]

				S. L. Osborn, S. J. Sohn, and A. Winoto Constitutive Phosphorylation Mutation in Fas-associated Death Domain (FADD) Results in Early Cell Cycle Defects J. Biol. Chem., August 3, 2007; 282(31): 22786 - 22792. [Abstract] [Full Text] [PDF]

				N. Mazurek, Y. J. Sun, K.-F. Liu, M. Z. Gilcrease, W. Schober, P. Nangia-Makker, A. Raz, and R. S. Bresalier Phosphorylated Galectin-3 Mediates Tumor Necrosis Factor-related Apoptosis-inducing Ligand Signaling by Regulating Phosphatase and Tensin Homologue Deleted on Chromosome 10 in Human Breast Carcinoma Cells J. Biol. Chem., July 20, 2007; 282(29): 21337 - 21348. [Abstract] [Full Text] [PDF]

				T. Yoshida, T. Maoka, S. K. Das, K. Kanazawa, M. Horinaka, M. Wakada, Y. Satomi, H. Nishino, and T. Sakai Halocynthiaxanthin and Peridinin Sensitize Colon Cancer Cell Lines to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Mol. Cancer Res., June 1, 2007; 5(6): 615 - 625. [Abstract] [Full Text] [PDF]

				A. Lissat, T. Vraetz, M. Tsokos, R. Klein, M. Braun, N. Koutelia, P. Fisch, M. E. Romero, L. Long, P. Noellke, et al. Interferon-{gamma} Sensitizes Resistant Ewing's Sarcoma Cells to Tumor Necrosis Factor Apoptosis-Inducing Ligand-Induced Apoptosis by Up-Regulation of Caspase-8 Without Altering Chemosensitivity Am. J. Pathol., June 1, 2007; 170(6): 1917 - 1930. [Abstract] [Full Text] [PDF]

				M. Gyrd-Hansen, T. Farkas, N. Fehrenbacher, L. Bastholm, M. Hoyer-Hansen, F. Elling, D. Wallach, R. Flavell, G. Kroemer, J. Nylandsted, et al. Apoptosome-Independent Activation of the Lysosomal Cell Death Pathway by Caspase-9 Mol. Cell. Biol., November 1, 2006; 26(21): 7880 - 7891. [Abstract] [Full Text] [PDF]

				S. Nakata, T. Yoshida, T. Shiraishi, M. Horinaka, J. Kouhara, M. Wakada, and T. Sakai 15-Deoxy-{Delta}12,14-prostaglandin J2 induces death receptor 5 expression through mRNA stabilization independently of PPAR{gamma} and potentiates TRAIL-induced apoptosis. Mol. Cancer Ther., July 1, 2006; 5(7): 1827 - 1835. [Abstract] [Full Text] [PDF]

				H. Z. Imtiyaz, S. Rosenberg, Y. Zhang, Z. S. M. Rahman, Y.-J. Hou, T. Manser, and J. Zhang The Fas-Associated Death Domain Protein Is Required in Apoptosis and TLR-Induced Proliferative Responses in B Cells. J. Immunol., June 1, 2006; 176(11): 6852 - 6861. [Abstract] [Full Text] [PDF]

				M. Horinaka, T. Yoshida, T. Shiraishi, S. Nakata, M. Wakada, and T. Sakai The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand. Mol. Cancer Ther., April 1, 2006; 5(4): 945 - 951. [Abstract] [Full Text] [PDF]

				H. Z. Imtiyaz, Y. Zhang, and J. Zhang Structural Requirements for Signal-induced Target Binding of FADD Determined by Functional Reconstitution of FADD Deficiency J. Biol. Chem., September 9, 2005; 280(36): 31360 - 31367. [Abstract] [Full Text] [PDF]

				Y. Zhang, S. Rosenberg, H. Wang, H. Z. Imtiyaz, Y.-J. Hou, and J. Zhang Conditional Fas-Associated Death Domain Protein (FADD):GFP Knockout Mice Reveal FADD Is Dispensable in Thymic Development but Essential in Peripheral T Cell Homeostasis J. Immunol., September 1, 2005; 175(5): 3033 - 3044. [Abstract] [Full Text] [PDF]

				M. L. Hyer, R. Croxton, M. Krajewska, S. Krajewski, C. L. Kress, M. Lu, N. Suh, M. B. Sporn, V. L. Cryns, J. M. Zapata, et al. Synthetic Triterpenoids Cooperate with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand to Induce Apoptosis of Breast Cancer Cells Cancer Res., June 1, 2005; 65(11): 4799 - 4808. [Abstract] [Full Text] [PDF]

				Y. Song and C. O. Jacob The Mouse Cell Surface Protein TOSO Regulates Fas/Fas Ligand-induced Apoptosis through Its Binding to Fas-associated Death Domain J. Biol. Chem., March 11, 2005; 280(10): 9618 - 9626. [Abstract] [Full Text] [PDF]

				L. Tourneur, S. Delluc, V. Levy, F. Valensi, I. Radford-Weiss, O. Legrand, J. Vargaftig, C. Boix, E. A. Macintyre, B. Varet, et al. Absence or Low Expression of Fas-Associated Protein with Death Domain in Acute Myeloid Leukemia Cells Predicts Resistance to Chemotherapy and Poor Outcome Cancer Res., November 1, 2004; 64(21): 8101 - 8108. [Abstract] [Full Text] [PDF]

				Y. Kotone-Miyahara, K. Yamashita, K.-K. Lee, S. Yonehara, T. Uchiyama, M. Sasada, and A. Takahashi Short-term delay of Fas-stimulated apoptosis by GM-CSF as a result of temporary suppression of FADD recruitment in neutrophils: evidence implicating phosphatidylinositol 3-kinase and MEK1-ERK1/2 pathways downstream of classical protein kinase C J. Leukoc. Biol., November 1, 2004; 76(5): 1047 - 1056. [Abstract] [Full Text] [PDF]

				Y. Lin, S. Choksi, H.-M. Shen, Q.-F. Yang, G. M. Hur, Y. S. Kim, J. H. Tran, S. A. Nedospasov, and Z.-g. Liu Tumor Necrosis Factor-induced Nonapoptotic Cell Death Requires Receptor-interacting Protein-mediated Cellular Reactive Oxygen Species Accumulation J. Biol. Chem., March 12, 2004; 279(11): 10822 - 10828. [Abstract] [Full Text] [PDF]

				E. Mezosi, S. H. Wang, S. Utsugi, L. Bajnok, J. D. Bretz, P. G. Gauger, N. W. Thompson, and J. R. Baker Jr. Interleukin-1{beta} and Tumor Necrosis Factor (TNF)-{alpha} Sensitize Human Thyroid Epithelial Cells to TNF-Related Apoptosis-Inducing Ligand-Induced Apoptosis through Increases in Procaspase-7 and Bid, and the Down-Regulation of p44/42 Mitogen-Activated Protein Kinase Activity J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 250 - 257. [Abstract] [Full Text] [PDF]

				J. H. Song, D. K. Song, M. Herlyn, K. C. Petruk, and C. Hao Cisplatin Down-Regulation of Cellular Fas-associated Death Domain-like Interleukin-1{beta}-converting Enzyme-like Inhibitory Proteins to Restore Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis in Human Melanoma Cells Clin. Cancer Res., September 15, 2003; 9(11): 4255 - 4266. [Abstract] [Full Text] [PDF]

				R. Greil, G. Anether, K. Johrer, and I. Tinhofer Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools J. Leukoc. Biol., September 1, 2003; 74(3): 311 - 330. [Abstract] [Full Text] [PDF]

				D. J. Buchsbaum, T. Zhou, W. E. Grizzle, P. G. Oliver, C. J. Hammond, S. Zhang, M. Carpenter, and A. F. LoBuglio Antitumor Efficacy of TRA-8 Anti-DR5 Monoclonal Antibody Alone or in Combination with Chemotherapy and/or Radiation Therapy in a Human Breast Cancer Model Clin. Cancer Res., September 1, 2003; 9(10): 3731 - 3741. [Abstract] [Full Text] [PDF]

				D. R. Beisner, I. H. Chu, A. F. Arechiga, S. M. Hedrick, and C. M. Walsh The Requirements for Fas-Associated Death Domain Signaling in Mature T Cell Activation and Survival J. Immunol., July 1, 2003; 171(1): 247 - 256. [Abstract] [Full Text] [PDF]

				D. D. Bannerman and S. E. Goldblum Mechanisms of bacterial lipopolysaccharide-induced endothelial apoptosis Am J Physiol Lung Cell Mol Physiol, June 1, 2003; 284(6): L899 - L914. [Abstract] [Full Text] [PDF]

<